BMS's ipilimumab faces three-month US delay for melanoma
This article was originally published in Scrip
Executive Summary
The US FDA has extended by three months its review period of the BLA for Bristol-Myers Squibb's ipilimumab (brand name Yervoy), a novel anti-CTLA-4 immunotherapy to treat previously treated advanced melanoma.